Vaxart, Inc.
NASDAQ:VXRT · NASDAQ Capital Market
-$0.01 today
Vol 0.35M · Avg 0.44M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $16.3M +124.4% | -$66.9M +18.8% | -$82.5M +23.5% | -$107.8M -52.9% | -$70.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $8.6M -3.1% | $8.8M +2.6% | $8.6M +48.6% | $5.8M +38.0% | $4.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 -100.0% | $4.1M +32.4% | $3.1M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $8.3M -27.7% | $11.5M -18.6% | $14.1M +4.0% | $13.6M +53.2% | $8.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$22.6M -791.7% | $3.3M +130.1% | -$10.8M -130.9% | -$4.7M -121.6% | -$2.1M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$39.4M -1330.3% | -$2.8M +7.9% | -$3.0M -5958.8% | $51.0K -80.6% | $263.0K | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 +100.0% | -$7.1M | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $14.6M +177.6% | $5.3M +315.8% | -$2.4M -784.6% | $357.0K -78.0% | $1.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $2.2M +193.0% | $742.0K +113.7% | -$5.4M -370.9% | $2.0M +149.9% | -$4.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$2.9M -105.9% | -$1.4M -1448.1% | $106.0K +101.8% | -$5.8M -70.4% | -$3.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $7.7M +117.2% | -$44.8M +36.5% | -$70.5M +25.7% | -$94.8M -58.4% | -$59.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$145.0K +73.8% | -$554.0K +70.4% | -$1.9M +80.5% | -$9.6M -86.2% | -$5.2M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 -100.0% | $120.0K -98.9% | $10.8M +323.9% | -$4.8M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$19.0M +65.0% | -$54.3M -97.6% | -$27.5M +50.0% | -$55.0M -22.8% | -$44.8M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $40.0M -8.0% | $43.5M -40.6% | $73.2M +65.6% | $44.2M +675.4% | $5.7M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$4.2M +57.8% | -$9.9M | $0 +100.0% | -$10.8M | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $16.6M +178.0% | -$21.3M -148.5% | $44.0M +315.3% | -$20.4M +58.4% | -$49.1M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $4.4M -92.2% | $56.8M +277.8% | $15.0M -12.8% | $17.2M -85.9% | $122.2M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$199.0K +7.0% | -$214.0K -200.5% | $213.0K -5.3% | $225.0K -93.7% | $3.6M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $4.2M -92.5% | $56.6M +271.1% | $15.2M -12.7% | $17.5M -86.1% | $125.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $28.6M +400.1% | -$9.5M +15.4% | -$11.3M +88.5% | -$97.7M -679.2% | $16.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $7.6M +116.7% | -$45.3M +37.3% | -$72.3M +30.7% | -$104.4M -60.6% | -$65.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$155.81M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
SEC Filings
Recent regulatory filings
No filings found.
Does VXRT generate free cash flow?
Vaxart, Inc. (VXRT) generated $7.57M of free cash flow in fiscal 2025.
How much operating cash flow does VXRT produce?
Operating cash flow was $7.71M, before capital expenditures of $145,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.